Pyripyropene A, an Acyl–Coenzyme A:Cholesterol Acyltransferase 2–Selective Inhibitor, Attenuates Hypercholesterolemia and Atherosclerosis in Murine Models of Hyperlipidemia | Zendy

Taichi Ohshiro | Zendy; Daisuke Matsuda | Zendy; K Sakai | Zendy; Chiara Degirolamo | Zendy; Hiroaki Yagyu | Zendy; Lawrence L. Rudel | Zendy; Satoshi Ōmura | Zendy; Shun Ishibashi | Zendy; Hiroshi Tomoda | Zendy

Open Access

Pyripyropene A, an Acyl–Coenzyme A:Cholesterol Acyltransferase 2–Selective Inhibitor, Attenuates Hypercholesterolemia and Atherosclerosis in Murine Models of Hyperlipidemia

Author(s) -

Taichi Ohshiro,

Daisuke Matsuda,

K Sakai,

Chiara Degirolamo,

Hiroaki Yagyu,

Lawrence L. Rudel,

Satoshi Ōmura,

Shun Ishibashi,

Hiroshi Tomoda

Publication year - 2011

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.111.223552

Subject(s) - sterol o acyltransferase , very low density lipoprotein , chemistry , cholesterol , cholesteryl ester , in vivo , hyperlipidemia , intermediate density lipoprotein , acyl coa , apolipoprotein b , lipoprotein , endocrinology , medicine , biochemistry , biology , enzyme , diabetes mellitus , microbiology and biotechnology

Pyripyropene A (PPPA) of fungal origin is the first compound that has been found to strongly and selectively inhibit acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) isozyme activity in vitro. The purpose of the present study was to investigate in vivo efficacy of the ACAT2-selective inhibitor in atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research